精神健康药物基因组学测试(第一部分):记录早期采用者对八种情况的使用看法。

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Personalized medicine Pub Date : 2021-05-01 Epub Date: 2021-03-17 DOI:10.2217/pme-2020-0083
Beatriz Manzor Mitrzyk, Melissa A Plegue, Reema Kadri, Shivang U Danak, Joseph D Hubbard, Emily A Kaip, Dana N Roberson, Vicki L Ellingrod, Karen B Farris, Mack T Ruffin, Michael S Klinkman, Lorraine R Buis
{"title":"精神健康药物基因组学测试(第一部分):记录早期采用者对八种情况的使用看法。","authors":"Beatriz Manzor Mitrzyk,&nbsp;Melissa A Plegue,&nbsp;Reema Kadri,&nbsp;Shivang U Danak,&nbsp;Joseph D Hubbard,&nbsp;Emily A Kaip,&nbsp;Dana N Roberson,&nbsp;Vicki L Ellingrod,&nbsp;Karen B Farris,&nbsp;Mack T Ruffin,&nbsp;Michael S Klinkman,&nbsp;Lorraine R Buis","doi":"10.2217/pme-2020-0083","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> We sought to understand how early adopters used pharmacogenomic (PGx) testing for treating depression and attention deficient hyperactivity disorder (ADHD). <b>Patients & methods:</b> We conducted a phone survey with prescribers who had previously ordered an <i>Informed PGx</i> (Progenity, Inc., MI, USA) test. <b>Results:</b> We identified 1037 prescribers in our sampling period. Respondents (n = 64) were predominantly female (61.5%) and in pediatrics (n = 42; 64.6%). PGx testing was used for multiple scenarios (mean 3.3 ± 1.6); the most common was after no response to medication was observed (80%; 51/64). Most respondents state that test results typically reveal an altered metabolizer status. <b>Conclusion:</b> PGx test results ordered by early adopters often reveal altered metabolizers which leads them to change the depression/ADHD medication regimen. Future work should evaluate the clinical utility of PGx testing for depression/ADHD treatment.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 3","pages":"223-232"},"PeriodicalIF":1.7000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pharmacogenomic testing for mental health (Part I): documenting early adopter perceptions of use for eight scenarios.\",\"authors\":\"Beatriz Manzor Mitrzyk,&nbsp;Melissa A Plegue,&nbsp;Reema Kadri,&nbsp;Shivang U Danak,&nbsp;Joseph D Hubbard,&nbsp;Emily A Kaip,&nbsp;Dana N Roberson,&nbsp;Vicki L Ellingrod,&nbsp;Karen B Farris,&nbsp;Mack T Ruffin,&nbsp;Michael S Klinkman,&nbsp;Lorraine R Buis\",\"doi\":\"10.2217/pme-2020-0083\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> We sought to understand how early adopters used pharmacogenomic (PGx) testing for treating depression and attention deficient hyperactivity disorder (ADHD). <b>Patients & methods:</b> We conducted a phone survey with prescribers who had previously ordered an <i>Informed PGx</i> (Progenity, Inc., MI, USA) test. <b>Results:</b> We identified 1037 prescribers in our sampling period. Respondents (n = 64) were predominantly female (61.5%) and in pediatrics (n = 42; 64.6%). PGx testing was used for multiple scenarios (mean 3.3 ± 1.6); the most common was after no response to medication was observed (80%; 51/64). Most respondents state that test results typically reveal an altered metabolizer status. <b>Conclusion:</b> PGx test results ordered by early adopters often reveal altered metabolizers which leads them to change the depression/ADHD medication regimen. Future work should evaluate the clinical utility of PGx testing for depression/ADHD treatment.</p>\",\"PeriodicalId\":19753,\"journal\":{\"name\":\"Personalized medicine\",\"volume\":\"18 3\",\"pages\":\"223-232\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Personalized medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pme-2020-0083\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/3/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2020-0083","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

摘要

目的:我们试图了解早期采用者如何使用药物基因组学(PGx)测试来治疗抑郁症和注意力缺陷多动障碍(ADHD)。患者和方法:我们对之前订购Informed PGx (Progenity, Inc, MI, USA)测试的处方者进行了电话调查。结果:在我们的抽样期间,我们确定了1037名处方者。调查对象(n = 64)主要是女性(61.5%)和儿科(n = 42;64.6%)。PGx检测用于多种情况(平均3.3±1.6);最常见的是在观察到药物无反应后(80%;51/64)。大多数答复者表示,测试结果通常显示代谢状态的改变。结论:早期采用者要求的PGx测试结果经常显示代谢改变,从而导致他们改变抑郁/ADHD药物治疗方案。未来的工作应该评估PGx检测在抑郁症/多动症治疗中的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacogenomic testing for mental health (Part I): documenting early adopter perceptions of use for eight scenarios.

Aim: We sought to understand how early adopters used pharmacogenomic (PGx) testing for treating depression and attention deficient hyperactivity disorder (ADHD). Patients & methods: We conducted a phone survey with prescribers who had previously ordered an Informed PGx (Progenity, Inc., MI, USA) test. Results: We identified 1037 prescribers in our sampling period. Respondents (n = 64) were predominantly female (61.5%) and in pediatrics (n = 42; 64.6%). PGx testing was used for multiple scenarios (mean 3.3 ± 1.6); the most common was after no response to medication was observed (80%; 51/64). Most respondents state that test results typically reveal an altered metabolizer status. Conclusion: PGx test results ordered by early adopters often reveal altered metabolizers which leads them to change the depression/ADHD medication regimen. Future work should evaluate the clinical utility of PGx testing for depression/ADHD treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信